Know Cancer

or
forgot password

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study


Phase 3
18 Years
79 Years
Not Enrolling
Male
Prostate Cancer

Thank you

Trial Information

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study


Inclusion Criteria:



1. Must be male > 18 and < 80 years of age

2. Have biopsy proven, low-risk, localized prostate cancer choosing expectant management
as primary treatment ≤ 1year. [For the purposes of assessing subject eligibility a
diagnostic biopsy must have included at least 10 cores, < 3 cores positive and < 50%
of any one core positive) and must have been obtained within 6 months of screening].
Initial diagnosis of T1a/T1b obtained during a TURP is not allowed

3. Gleason score ≤ 6 [Gleason pattern 4 or above must not be present on any biopsy
(initial or entry)]

4. Clinical stage T1c-T2a

5. Serum PSA ≤10 ng/mL (prior to biopsy)

6. Life expectancy greater than 5 years, as judged by the treating clinician/urologist

7. Able to swallow and retain oral medication

8. Hemoglobin A1c < 6.5%

9. Able and willing to participate in the full 3 years of the study

10. Able to understand instructions related to study procedures

11. Able to read and write (health outcome questionnaires are self-administered),
understand instructions related to study procedures and give written informed consent

Exclusion Criteria:

1. Subject that has ever been treated for prostate cancer with any of the following:

- Radiotherapy (external beam or brachytherapy)

- Chemotherapy

- Hormonal therapy (e.g., megestrol, medoxyprogesterone, cyproterone)

- Oral glucocorticoids

- GnRH analogues (e.g., leuprolide, goserelin, degarelix)

2. Current and/or previous use of the following medications:

- Use of 5α-reductase inhibitors (eg. Finasteride, Dutasteride) within the past 6
months of screening

- Drugs with antiandrogenic properties (e.g., flutamide, bicalutamide,
ketoconazole, progestational agents) within 6 months prior to screening

3. Previous or current diagnosis of type 1 or type 2 diabetes

4. Exposure to metformin within 12 months of screening

5. Planned or concurrent use of metformin hydrochloride, sulfonylureas,
thiazolidinediones, or insulin for any reason

6. Known hypersensitivity or intolerance to metformin hydrochloride

7. Any condition associated with increased risk of metformin hydrochloride-associated
lactic acidosis (e.g. congestive heart failure defines as NYHA class III or IV,
history of any type of acidosis, habitual intake of ≥ 4 alcoholic beverages per day)

8. Subject has had prior prostatic surgery including TUNA, TURP, TUIP, laser treatment,
thermotherapy, balloon dilatation, prosthesis, and ultrasound ablation within 3
months of screening

9. Participation in any investigational or marketed drug trial within 30 days prior to
screening or anytime during the study period. This includes any interventional or
exercise trials

10. Any unstable serious co-existing medical condition(s) including, but not limited to,
myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias,
clinically evident congestive heart failure, or cerebrovascular accident within 6
months prior to Screening visit

11. Abnormal liver function test:

- Total bilirubin > 1.8 X institutional upper limit of normal (ULN)

- Aspartate aminotransferase (AST) > 1.8 X institutional ULN

- Alanine aminotransferase (ALT) > 1.8 X institutional ULN

- Alkaline phosphatase (ALP) > 1.8 X institutional ULN

12. Serum creatinine > 1.8 X ULN

13. History of other malignancies, with the exception of adequately treated nonmelanoma
skin cancer, stage I melanoma, NMIBC or other solid tumors curatively treated with no
evidence of disease for at least 5 years

14. History or current evidence of substance abuse, as defined in DSM-IV, within 12
months of screening

15. History of any illness (including psychiatric) that, in the opinion of the
investigator, might confound the results of the study or pose additional risk to the
subject

16. No other concurrent metformin hydrochloride, sulfonylureas, thiazolidinediones, or
insulin for any reason

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Outcome Measure:

Time to progression

Outcome Description:

Time to progression - progression is defined as the earliest of the following events: Primary therapy for prostate cancer (e.g. prostatectomy, radiation, hormonal therapy) Pathological progression as defined as one of the following: i. At least 4 cores involved ii. At least 50% of any one core involved iii. Gleason pattern 4 or higher

Outcome Time Frame:

3 years

Safety Issue:

No

Principal Investigator

Neil Fleshner, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Health Network: Department of Surgical Oncology (Urology)

Authority:

Canada: Health Canada

Study ID:

MAST_001

NCT ID:

NCT01864096

Start Date:

August 2013

Completion Date:

August 2018

Related Keywords:

  • Prostate Cancer
  • localized
  • prostate
  • cancer
  • metformin
  • active surveillance
  • Prostatic Neoplasms

Name

Location